We are live on ! Find out more
VRAX icon

Virax Biolabs

5 hedge funds and large institutions have $424K invested in Virax Biolabs in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

642% more capital inflows, than outflows

Capital inflows: $464K | Capital outflows: $62.5K

2.03% more ownership

Funds ownership: 3% → 5.03% (+2%)

29% less funds holding

Funds holding: 7 → 5 (-2)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

Holders
5
Holders Change
-2
Holders Change %
-28.57%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

VRAX Hedge Fund Activity: Q3 2024 in Review

5 of the 6,990 institutional investors tracked by Wall St. Rank reported a position in Virax Biolabs (VRAX) for Q3 2024, worth a combined $424K — up 418% from $81.8K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of VRAX and 2 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 3 added.

The largest buyer was Renaissance Technologies, adding an estimated $309K. The largest seller was Virtu Financial, exiting entirely with an estimated $33K sold.

  • 5 institutional investors held Virax Biolabs (VRAX) as of Q3 2024, down from 7 in Q2 2024.
  • Funds reported $424K of Virax Biolabs stock for Q3 2024, up 418% quarter-over-quarter.
  • 2 funds opened new Virax Biolabs positions in Q3 2024 and 4 closed out, a net change of -2 holders.
  • The largest Virax Biolabs buyer in Q3 2024 was Renaissance Technologies, an estimated $309K added.
  • The largest Virax Biolabs seller in Q3 2024 was Virtu Financial, an estimated $33K sold.

Based on aggregated 13F filings for Q3 2024.